Document Detail

Short-term effects of growth hormone treatment on the upper airways of non severely obese children with Prader-Willi syndrome.
MedLine Citation:
PMID:  19498323     Owner:  NLM     Status:  MEDLINE    
AIMS: The aim of this study was to establish whether short-term GH treatment causes obstructive apnea in patients with Prader-Willi syndrome and normal upper airway patency. SUBJECTS AND METHODS: We performed an observational longitudinal 6-week GH treatment study. Thirty-four non-severely obese Prader-Willi syndrome patients (20 boys, age range 0.94-11.8 yr, median 2.24 yr) entered an observational longitudinal 6-week study. Sixteen boys received recombinant human GH (rhGH) treatment; the remaining 18 represented the control group and received no treatment. Polysomnography monitoring and othorhinolaringoiatric video endoscopy were performed one night before and after 6 weeks of rhGH treatment (0.03 mg/kg body weight/day). All patients underwent auxologic assessment, fasting blood glucose, insulin and IGF-I evaluation. The main polysomnographic parameter considered was total apnea hypopnea index, consisting of two components: central apnea hypopnea index and obstructive apnea hypopnea index. All patients were free of severe or moderate upper airway obstruction when rhGH treatment began. RESULTS: After 6 weeks of rhGH therapy, obstructive apnea hypopnea index increased in 8/16 (50%), decreased in 5/16 (31%), and did not change in 3/16 (19%) patients. The changes were not statistically significant. The rhGH-treated group did not differ from the control group for the apnea hypopnea index both before and after 6 weeks of treatment. Adenoids and tonsils showed a slight increase in 1 and 2 patients on rhGH treatment, respectively, and did not change in the untreated patients. CONCLUSIONS: Our data show that short-term rhGH treatment does not cause restrictions of the upper airways in patients with Prader-Willi syndrome and normal upper airway patency.
A Salvatoni; E Veronelli; L Nosetti; J Berini; S de Simone; L Iughetti; L Bosio; G Chiumello; G Grugni; G Del??; P Castelnuovo; G Trifir??; L Nespoli
Related Documents :
3178533 - Short course of albendazole therapy for neurocysticercosis.
9649453 - Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and ch...
21218663 - Radical perineal prostatectomy and early continence: outcomes after 120 cases.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-05-15
Journal Detail:
Title:  Journal of endocrinological investigation     Volume:  32     ISSN:  1720-8386     ISO Abbreviation:  J. Endocrinol. Invest.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-11-06     Completed Date:  2010-01-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806594     Medline TA:  J Endocrinol Invest     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  601-5     Citation Subset:  IM    
Pediatric Clinic, Insubria University, Varese, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / metabolism
Body Composition
Body Mass Index
Child, Preschool
Human Growth Hormone / therapeutic use*
Insulin / blood
Insulin Resistance / physiology
Obesity / complications*
Prader-Willi Syndrome* / drug therapy,  physiopathology
Recombinant Proteins / therapeutic use*
Sleep Apnea, Obstructive* / etiology,  physiopathology,  therapy
Trachea / drug effects*,  pathology
Reg. No./Substance:
0/Blood Glucose; 0/Recombinant Proteins; 11061-68-0/Insulin; 12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors.
Next Document:  Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after ...